InsiderPulseNo transactions found.
No financial data available for KLRA.
Company may not file with SEC or CIK is unresolved.
Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
U.S. IPO Weekly Recap: IPO Calendar Heats Up As AI Chipmaker Cerebras Rejoins The Public Pipeline
Kailera Therapeutics indicated to open at $24, IPO priced at $16
Weight loss drug developer Kailera climbs 50% on trading debut
GLP-1 developer Kailera prices IPO at $16 per share to raise $625M
Kailera Therapeutics Announces Pricing of Initial Public Offering
Kailera Therapeutics Pursues IPO On Promising GLP-1 Trial Results
GLP-1 developer Kailera, proteomics firm Alamar file for U.S. IPOs